Activating the Immune System to Attack Cancer

Seagen, through its industry-leading work in the field of antibody-drug conjugates (ADCs), has a substantial portfolio of cancer targets and tumor-specific monoclonal antibodies from which programs will be selected for the collaboration. The bispecific drug candidates in this alliance will be designed to enable the patient's immune cells to attack tumors preferentially. The companies will pursue multiple antibody-Anticalin fusion proteins during the research phase, and Seagen has the option to select up to three therapeutic programs for further development.